Hippo pathway in cancer cells induces NCAM1<sup>+</sup>αSMA<sup>+</sup> fibroblasts to modulate tumor microenvironment
Issued Date
2024-12-01
Resource Type
eISSN
23993642
Scopus ID
2-s2.0-85206620930
Journal Title
Communications Biology
Volume
7
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Communications Biology Vol.7 No.1 (2024)
Suggested Citation
Thinyakul C., Sakamoto Y., Shimoda M., Liu Y., Thongchot S., Reda O., Nita A., Sakamula R., Sampattavanich S., Maeda A., Chunthaboon P., Nduru D., Niimura M., Kanamori Y., Thuwajit P., Nakayama K.I., Guan K.L., Satou Y., Thuwajit C., Moroishi T. Hippo pathway in cancer cells induces NCAM1<sup>+</sup>αSMA<sup>+</sup> fibroblasts to modulate tumor microenvironment. Communications Biology Vol.7 No.1 (2024). doi:10.1038/s42003-024-07041-4 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/101753
Title
Hippo pathway in cancer cells induces NCAM1<sup>+</sup>αSMA<sup>+</sup> fibroblasts to modulate tumor microenvironment
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Cancer cells adeptly manipulate the tumor microenvironment (TME) to evade host antitumor immunity. However, the role of cancer cell-intrinsic signaling in shaping the immunosuppressive TME remains unclear. Here, we found that the Hippo pathway in cancer cells orchestrates the TME by influencing the composition of cancer-associated fibroblasts (CAFs). In a 4T1 mouse breast cancer model, Hippo pathway kinases, large tumor suppressor 1 and 2 (LATS1/2), promoted the formation of neural cell adhesion molecule 1 (NCAM1)+alpha-smooth muscle actin (αSMA)+ CAFs expressing the transforming growth factor-β, which is associated with T cell inactivation and dysfunction. Depletion of LATS1/2 in cancer cells resulted in a less immunosuppressive TME, indicated by the reduced proportions of NCAM1+αSMA+ CAFs and dysfunctional T cells. Notably, similar Hippo pathway-induced NCAM1+αSMA+ CAFs were observed in human breast cancer, highlighting the potential of TME-manipulating strategies to reduce immunosuppression in cancer immunotherapy. (Figure presented.)